CTIS2023-505318-97-00招募中1 期
A Randomized Intervention, Multi-Center Study to Determine the Role of Dexamethasone eye drops against proliferative retinopathy of prematurity
Vaestra Goetalandsregionen0 个研究点目标入组 100 人开始时间: 2023年8月17日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 17（—）
- 性别
- All
入选标准
- •1)Gestational age <30 weeks, 2)Zone I ROP without plus disease with either a. ROP Stage 1, or ROP Stage 2 or Zone II ROP without plus disease with either a.Posterior ROP stage 2 or b. ROP stage 3 with or without notch in zone I, 3)ROP stage documented using RetCam photography and confirmed by two ophthalmologists, 4)Parent’s informed (oral and written information) consent.
排除标准
- •1)Ongoing ocular infection, 2)If the patient is judged unsuitable for the study by treating neonatologist/paediatrician or ophthalmologist for any other reason
研究者
相似试验
进行中（未招募）
1 期
Can steroid eyedrops prevent severe ROPRetinopathy of PrematurityEUCTR2020-004933-19-SERegion Västra Götaland, Sahlgrenska Universitetssjukhuset90
招募中
Unknown
A Multicenter Prospective Randomized Interventional Study Examining the Impact of Wide Interlesion Distance in High Power Short Duration Atrial Fibrillation Ablation Using the TactiFlexAtrial fibrillationJPRN-jRCT1042230052aruse Yoshihisa204
已完成
不适用
GIVE UP FOR GOOD- A study to evaluate the effectiveness of a pharmacist-led multidisciplinary smoking cessation intervention for smokers admitted to public hospitals.Tobacco use and dependenceSmoking CessationPublic Health - Health service researchMental Health - AddictionACTRN12612000368831Monash University600
进行中（未招募）
1 期
A Randomized Study to Determine the Effect of Triheptanoin in Pediatric Patients with Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)CTIS2023-509809-76-00ltragenyx Pharmaceutical Inc.70
进行中（未招募）
1 期
A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Ustekinumab (AVT04) and Stelara® in Patients With Moderate to Severe Chronic Plaque-type PsoriasisEUCTR2020-004493-22-PLAlvotech Swiss AG528